“… 10 Albumin was also regarded as a reliable indicator of the prognosis of patients with severe COVID. 11 Hypoalbuminemia is common in SARS patients, and inversion of the A/G ratio can indicate SARS patients earlier. 12 , 13 Hypoalbuminemia negatively affects the immune response system and increases short-term mortality in hospitalized stroke patients with acute infectious diseases.…”
Background: Hypoalbuminemia has been reported in COVID-19 patients. Exploring the influencing factors and possible adverse consequences of albumin reduction may provide some guidance for the treatment of COVID-19 patients. Methods: In this multicentre retrospective study, we collected information including demographics, comorbidities, clinical symptoms, complications, laboratory tests, treatment, and outcomes of patients diagnosed with COVID-19 from three hospitals in Wuhan, China. We compared the indexes between patients with hypoalbuminemia and normal albumin. Regression model was used to evaluate various influencing factors of patients with hypoalbuminemia and their relationship with clinical outcomes. We also compared the changes of particular laboratory indexes in patients with hypoalbuminemia before and after enteral nutrition therapy. Results: A total of 482 patients were enrolled in the study. About 53.7% patients developed hypoalbuminemia during admission. Patients with hypoalbuminemia were older, had a higher proportion of combined diabetes mellitus, fever, dyspnea, and natriuresis, and had a relatively poorer prognosis than patients with normal albumin. Patients with hypoalbuminemia had higher levels of CRP, leukocytes, ALT, AST, total bilirubin, ALP, GGT, LDH, creatine kinase, D-dimer, globulin, and lower levels of lymphocytes and eosinophils. Severe, older, anorexia, elevated CRP, and decreased lymphocytes were the independent predictors for decreased albumin in COVID-19 patients. In addition, decreased albumin is correlated with adverse outcomes. Nutritional support therapy to correct serum albumin may improve patient outcomes. Conclusion: COVID-19 patients with hypoalbuminemia tend to have more severe clinical manifestations and more abnormal biochemical tests, which may result in poorer clinical outcomes. Nutritional support therapy may improve the clinical outcome of these patients.
“… 10 Albumin was also regarded as a reliable indicator of the prognosis of patients with severe COVID. 11 Hypoalbuminemia is common in SARS patients, and inversion of the A/G ratio can indicate SARS patients earlier. 12 , 13 Hypoalbuminemia negatively affects the immune response system and increases short-term mortality in hospitalized stroke patients with acute infectious diseases.…”
Background: Hypoalbuminemia has been reported in COVID-19 patients. Exploring the influencing factors and possible adverse consequences of albumin reduction may provide some guidance for the treatment of COVID-19 patients. Methods: In this multicentre retrospective study, we collected information including demographics, comorbidities, clinical symptoms, complications, laboratory tests, treatment, and outcomes of patients diagnosed with COVID-19 from three hospitals in Wuhan, China. We compared the indexes between patients with hypoalbuminemia and normal albumin. Regression model was used to evaluate various influencing factors of patients with hypoalbuminemia and their relationship with clinical outcomes. We also compared the changes of particular laboratory indexes in patients with hypoalbuminemia before and after enteral nutrition therapy. Results: A total of 482 patients were enrolled in the study. About 53.7% patients developed hypoalbuminemia during admission. Patients with hypoalbuminemia were older, had a higher proportion of combined diabetes mellitus, fever, dyspnea, and natriuresis, and had a relatively poorer prognosis than patients with normal albumin. Patients with hypoalbuminemia had higher levels of CRP, leukocytes, ALT, AST, total bilirubin, ALP, GGT, LDH, creatine kinase, D-dimer, globulin, and lower levels of lymphocytes and eosinophils. Severe, older, anorexia, elevated CRP, and decreased lymphocytes were the independent predictors for decreased albumin in COVID-19 patients. In addition, decreased albumin is correlated with adverse outcomes. Nutritional support therapy to correct serum albumin may improve patient outcomes. Conclusion: COVID-19 patients with hypoalbuminemia tend to have more severe clinical manifestations and more abnormal biochemical tests, which may result in poorer clinical outcomes. Nutritional support therapy may improve the clinical outcome of these patients.
“…Lower serum albumin can be indicative of malnutrition, underlying disease, or infectious processes [27] . Albumin was also regarded as a reliable indicator of the prognosis of patients with severe COVID-19 infection [28] . Hypoalbuminemia is very frequently noticed in patients with conditions like diabetes, hypertension and chronic heart failure, and these patients are statistically most vulnerable to SARS-CoV-2 infection [29] .…”
Section: Hypoalbuminemia: An Indicator Of the Severity And Prognosis Of Covid-19 Patientsmentioning
The severe acute respiratory syndrome corona virus-2 (SARS-CoV-2) keeps on destroying normal social integrity worldwide, bringing about extraordinary medical services, cultural and financial interruption. Individuals with diabetes have been demonstrated to be at higher risk of complications and even death when exposed to SARS-CoV-2. Regardless of pandemic scale infection, there is presently limited comprehension on the potential impact of SARS-CoV-2 on individuals with diabetes. Human serum albumin (HSA) is the most abundant circulating plasma protein in human serum and attracted more interest from researchers because most susceptible to non-enzymatic glycation reactions. Albumin down-regulates the expression of ACE2 that is the target receptor of COVID-19. Hypoalbuminemia, coagulopathy, and vascular disease have been connected in COVID-19 and appear to predict outcomes independent of age and morbidity. This review discusses the most recent evidence that the ACE/ACE2 ratio could influence by human serum albumin both the susceptibility of individuals to SARS-CoV-2 infection and the outcome of the COVID-19 disease.
“…Extreme between-study heterogeneity was observed (I 2 = 93.5%, p < 0.001). HBDH concentrations remained significantly higher (SMD = 1.00, 95% CI 0.72 to 1.27, p = 0.001; I 2 = 93.8%, p < 0.001) in patients with high severity or non-survivor status after excluding the three largest studies (> 2,500 participants) [ 39 , 47 , 50 ], accounting for ~ 62% of the overall sample size. Fig.…”
Section: Resultsmentioning
confidence: 98%
“…Nineteen studies were retrospective [ 38 , 39 , 41 – 47 , 49 – 55 , 57 – 59 ], whilst the remaining three did not report the study design [ 40 , 48 , 56 ]. Clinical endpoints included disease severity based on current clinical guidelines (13 studies) [ 39 , 41 , 43 , 45 – 48 , 50 – 52 , 55 , 59 ], disease progress (two studies) [ 40 , 56 ], occurrence of ARDS (one study) [ 54 ], and survival (six studies) [ 38 , 42 , 44 , 49 , 57 , 58 ]. In all studies, serum HBDH concentrations were measured on admission.…”
Section: Resultsmentioning
confidence: 99%
“…The risk of bias was considered to be low in 19 studies [ 38 – 40 , 42 – 46 , 48 – 50 , 52 – 59 ], and moderate in the remaining three [ 41 , 47 , 51 ].…”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
